© Copyright Acquisition International 2024 - All Rights Reserved.

Article Image - Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Posted 7th March 2016

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health

Avant Diagnostics, Inc, a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acqu

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Avant Diagnostics and Amarantus Diagnostics to Combine with Theranostics Health
Image

Avant Diagnostics, Inc., a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, Inc, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc, today announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Incorporated, adding key CLIA laboratory and intellectual property capabilities to Avant’s previously announced letter of intent to merge with Amarantus Diagnostics (collectively, the “Transactions”).

THI currently generates over $1.5M in services revenue from some of the world’s leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue. The companies will be holding a conference call to discuss the business combination today at 4:30 PM ET. To access the conference call please dial 215-383-1625 or toll free 800-356-8278; access code 135394.

Under the terms of the letter of intent, Avant shall issue to THI 25 million shares of its common stock upon the closing. Amarantus BioScience has provided a convertible note of $400,000 to THI to facilitate the transaction that will be assumed by Avant upon closing of the transactions. As previously disclosed, Avant plans to issue 80 million shares of its common stock to Amarantus Biosciences upon completion of its merger with Amarantus Diagnostics. The Transactions are expected to close in the first half of 2016, and are subject to customary closing conditions.

Gerald E. Commissiong, President & CEO of Amarantus said:

“THI is a leader in the area of signal transduction biology, where they have been able to attract an A-list of pharmaceutical customers collaborating with the company to evaluate the therapeutic benefit and potential of their drug candidates using THI’s proprietary assays.

“In addition, THI has a CLIA lab where Amarantus’ Diagnostics has established operations over the course of the first quarter that will allow for CLIA validation and commercial launch of the combined company’s suite of high-value, proprietary diagnostics in the areas of oncology and neurology. THI’s sales channel into the pharmaceutical industry will provide important leverage for the combined company to market the LymPro Test® for Alzheimer’s disease. We could not have picked a better partner to bring Avant and Amarantus’ Diagnostics leading-edge intellectual property in diagnostics and biomarkers to the market.”

Gregg Linn, President & CEO of Avant Diagnostics added:

“Key to the business case for the merged company is THI’s impressive pharma services revenue base and sales channel in the area of cell signaling biology. In addition to this, THI’s CLIA laboratory provides the combined company with the infrastructure to launch OvaDx®, MSPrecise® and LymPro Test in a regulatory compliant environment that has been vetted by some of the world’s top pharmaceutical companies. THI’s laboratory meets the highest quality standards under CLIA/CAP which should give both our pharmaceutical and commercial customers great confidence in the information generated in THI’s laboratory.”

THI’s core business is centred on providing pharmaceutical and biotechnical companies access to its technology for quantitatively measuring the activation status of key proteins and signal transduction pathways that are dysregulated in multiple disease processes via its Reverse-phase Protein Array (RPPA) platform. THI is experienced in running CAP-accredited assays in its CLIA laboratory for predicting response to therapies in difficult to treat cancers.  THI believes that, while genomic approaches may identify potential activating mutations in diseased tissues, measuring the actual activation status of the protein drug targets and the signal transduction pathways that they regulate, provides physicians with much-needed evidence that a particular therapeutic strategy can provide benefits to the patient.  THI has launched tests, TheraLink® Assays, for guiding therapeutic decisions in breast and colorectal cancer. The post-merger Avant Diagnostics will further build on its recognized scientific expertise in the area of cell cycle biology to increase its pharma services revenues and provide therapy guiding diagnostics in difficult to treat conditions.

Glenn Hoke, PhD, Chief Executive Officer of THI added:

“After an extensive evaluation of the diagnostics market, we believe that we have found the best potential partners in Avant and Amarantus. It is clear that we will be expanding our CLIA offerings with much needed tests such as OvaDx in cancer and MSPrecise in neurology, while also providing significant additional pharma services business development opportunities with the LymPro Test. With platforms in microarray proteomics, ELISA, flow cytometry and ‘next-gen’ sequencing, the combined company’s capabilities will allow it to add cross-platform diagnostics as we grow into the future.”

 

 

Categories: Innovation, M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
November Winners’ Directory
Finance
02/12/2016November Winners’ Directory

November Winners’ Directory

Read Full PostRead - Eye Icon
BMW Group Achieves Best-ever March Sales
Strategy
14/04/2015BMW Group Achieves Best-ever March Sales

Deliveries of BMW Group vehicles in March reached a new high contributing to the company's best ever first quarter sales figures

Read Full PostRead - Eye Icon
A Most Effective Way to Finance Working Capital
Finance
13/02/2024A Most Effective Way to Finance Working Capital

With a portfolio of more than 15,000 happy customers relying on it to aid in the optimisation of their working capital and the reduction of risk to their supply chains, eFactor Network SAPI de CV boasts a state-of-the-art financing platform that improves overa

Read Full PostRead - Eye Icon
How to build and manage credible partnerships and affiliations in business
Finance
21/02/2018How to build and manage credible partnerships and affiliations in business

The rapid rise of brands and companies partnering with experts and influencers to endorse products or services has been ever-increasing in our social media focused world.

Read Full PostRead - Eye Icon
Insurance Company Approached You To Settle A Claim: Here’s What To Do
News
07/03/2022Insurance Company Approached You To Settle A Claim: Here’s What To Do

If you have been injured in an accident, you are probably in a lot of pain. You may have to attend multiple doctor’s appointments and miss plenty of work. You just want this all to be over with and to get back to your normal life.  When an insurance

Read Full PostRead - Eye Icon
Paying the Price: Late Payments Forcing UK Businesses to Make Tough Decisions
Finance
17/02/2015Paying the Price: Late Payments Forcing UK Businesses to Make Tough Decisions

Although late payments are something almost every business comes across, in the UK there is currently a culture of unpaid payment causing a domino effect of debt across the British Isles.

Read Full PostRead - Eye Icon
Centum Acquisition of a Controlling Stake in K-Rep Bank
M&A
01/02/2015Centum Acquisition of a Controlling Stake in K-Rep Bank

Centum, the East African investment firm, announced the acquisition of a controlling stake in Kenyan bank K-REP Bank Limited.

Read Full PostRead - Eye Icon
Working From Home Can Slash Payback Periods for EV Drivers
Finance
10/11/2022Working From Home Can Slash Payback Periods for EV Drivers

According to insight from the Office for National Statistics (ONS), more than 38% of the UK workforce now enjoy either a part-hybrid or totally remote role. While sceptics have suggested that this trend will begin to fall in-line with retreating COVID-19 cases

Read Full PostRead - Eye Icon
I-NGEN-ious Advertising
Innovation
08/10/2021I-NGEN-ious Advertising

As one of Canada’s Fastest-Growing Companies, NGEN Communications knows what it takes to drive business growth. Thus, having helped emerging brands across a vast selection of industries to achieve their potential through comprehensive marketing strategies, N



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow